KURA Kura Oncology Inc

Price (delayed)

$21.08

Market cap

$1.61B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.17

Enterprise value

$1.58B

Tipifarnib, is a potent, selective and orally bioavailable inhibitor of farnesyl transferase in-licensed from Janssen. Previously, tipifarnib was studied in more than 5,000 cancer patients and showed compelling and durable ...

Highlights
The equity has grown by 28% YoY and by 27% from the previous quarter
The quick ratio has grown by 36% from the previous quarter but it has contracted by 23% YoY
The debt is up by 25% year-on-year
Kura Oncology's net income has decreased by 22% YoY and by 10% from the previous quarter

Key stats

What are the main financial stats of KURA
Market
Shares outstanding
76.18M
Market cap
$1.61B
Enterprise value
$1.58B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.18
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$166.5M
EBITDA
-$165.63M
Free cash flow
-$138.01M
Per share
EPS
-$2.17
Free cash flow per share
-$1.64
Book value per share
$6.63
Revenue per share
$0
TBVPS
$6.6
Balance sheet
Total assets
$553.91M
Total liabilities
$48.82M
Debt
$16.97M
Equity
$505.08M
Working capital
$505.57M
Liquidity
Debt to equity
0.03
Current ratio
16.67
Quick ratio
16.34
Net debt/EBITDA
0.15
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-34.1%
Return on equity
-37.5%
Return on invested capital
-37.8%
Return on capital employed
-31.9%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

KURA stock price

How has the Kura Oncology stock price performed over time
Intraday
1.59%
1 week
-9.26%
1 month
0.67%
1 year
91.46%
YTD
46.59%
QTD
2.38%

Financial performance

How have Kura Oncology's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$183.69M
Net income
-$168.09M
Gross margin
N/A
Net margin
N/A
The company's operating income fell by 28% YoY and by 11% QoQ
Kura Oncology's net income has decreased by 22% YoY and by 10% from the previous quarter

Growth

What is Kura Oncology's growth rate over time

Valuation

What is Kura Oncology stock price valuation
P/E
N/A
P/B
3.18
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS fell by 6% YoY and by 4.3% QoQ
The stock's P/B is 38% above its last 4 quarters average of 2.3 and 22% above its 5-year quarterly average of 2.6
The equity has grown by 28% YoY and by 27% from the previous quarter

Efficiency

How efficient is Kura Oncology business performance
The return on equity has declined by 15% year-on-year and by 3.3% since the previous quarter
The ROA has contracted by 12% YoY and by 3% from the previous quarter
The return on invested capital has declined by 7% year-on-year and by 3.6% since the previous quarter

Dividends

What is KURA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KURA.

Financial health

How did Kura Oncology financials performed over time
KURA's total liabilities has soared by 59% year-on-year but it is down by 5% since the previous quarter
The current ratio rose by 36% QoQ but it fell by 23% YoY
The debt is 97% smaller than the equity
The equity has grown by 28% YoY and by 27% from the previous quarter
The debt to equity has declined by 25% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.